← Eichor
Condition: Metastatic Urothelial Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07390617This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05394337Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Yale University · NCT07048457Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 · 6 location(s) · Deciphera Pharmaceuticals, LLC · NCT06966024Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Phase 4 · 13 location(s) · Astellas Pharma Global Development, Inc. · NCT06862219CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04235777AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT06138561Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Phase 2 · 135 location(s) · Gilead Sciences · NCT03547973SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 · 30 location(s) · Pfizer · NCT07090499Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · 221 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · 286 location(s) · Eli Lilly and Company · NCT07218380Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Fox Chase Cancer Center · NCT072219429MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Phase 3 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06592326A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresecta
Phase 3 · 1 location(s) · Shanghai Miracogen Inc. · NCT05754853Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Local
Phase 2 · 1 location(s) · Xiujuan Qu · NCT07506057Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours
Phase 4 · 1 location(s) · University of Roma La Sapienza · NCT05962541
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.